{"id":"beraprost-sodium-modified-release","safety":{"commonSideEffects":[{"rate":"20%","effect":"Headache"},{"rate":"15%","effect":"Flushing"},{"rate":"10%","effect":"Diarrhea"}]},"_chembl":{"chemblId":"CHEMBL1207745","moleculeType":"Small molecule","molecularWeight":"398.50"},"_dailymed":null,"mechanism":{"_ai_source":"featherless-qwen","explanation":"Beraprost sodium mimics the natural prostacyclin, which binds to the prostacyclin (IP) receptor, leading to vasodilation and inhibition of platelet aggregation, thereby improving blood flow and reducing the risk of thrombosis.","oneSentence":"Beraprost sodium is a prostacyclin analog that acts on the IP receptor to dilate blood vessels and inhibit platelet aggregation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:22:51.300Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Pulmonary arterial hypertension"},{"name":"Chronic thromboembolic pulmonary hypertension"}]},"trialDetails":[{"nctId":"NCT01966302","phase":"PHASE2","title":"Compassionate Use of Beraprost Sodium 314d Modified Release for Patients With Pulmonary Arterial Hypertension (PAH)","status":"COMPLETED","sponsor":"Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center","startDate":"2013-11","conditions":"Pulmonary Arterial Hypertension","enrollment":1},{"nctId":"NCT00989963","phase":"PHASE2","title":"Dose-response Study of the Safety and Efficacy of Beraprost Sodium Modified Release (BPS-MR) in Patients With Pulmonary Arterial Hypertension (PAH)","status":"COMPLETED","sponsor":"Lung Biotechnology PBC","startDate":"2010-02-01","conditions":"Pulmonary Arterial Hypertension","enrollment":36},{"nctId":"NCT03657095","phase":"PHASE3","title":"A Study With BPS-314d-MR-PAH-303 in Participants With Pulmonary Arterial Hypertension","status":"TERMINATED","sponsor":"Lung Biotechnology PBC","startDate":"2018-12-10","conditions":"Pulmonary Arterial Hypertension","enrollment":112},{"nctId":"NCT01908699","phase":"PHASE3","title":"Beraprost-314d Added-on to Tyvaso® (BEAT)","status":"COMPLETED","sponsor":"Lung Biotechnology PBC","startDate":"2013-05-31","conditions":"Pulmonary Arterial Hypertension","enrollment":273},{"nctId":"NCT00781885","phase":"PHASE2","title":"A Multi-Center, Open-Label, Multiple Dose, Dose Finding Study Exploring the Safety and Tolerability of Beraprost Sodium Modified Release in PAH Patients","status":"COMPLETED","sponsor":"Lung Biotechnology PBC","startDate":"2009-01-31","conditions":"Pulmonary Arterial Hypertension","enrollment":19},{"nctId":"NCT00792571","phase":"PHASE2","title":"An Open-Label Extension of BPS-MR-PAH-201 in Pulmonary Arterial Hypertension (PAH) Patients","status":"COMPLETED","sponsor":"Lung Biotechnology PBC","startDate":"2009-02-28","conditions":"Pulmonary Arterial Hypertension","enrollment":18},{"nctId":"NCT00990314","phase":"PHASE2","title":"Extension of BPS-MR-PAH-203 in Pulmonary Arterial Hypertension (PAH) Patients","status":"COMPLETED","sponsor":"Lung Biotechnology PBC","startDate":"2009-11-30","conditions":"Pulmonary Arterial Hypertension","enrollment":31},{"nctId":"NCT01458236","phase":"PHASE3","title":"A Multinational, Multicenter, Study to Assess the Efficacy and Safety of BPS-314d-MR in Subjects With Pulmonary Arterial Hypertension Currently Receiving Treatment With an Endothelin Receptor Antagonist and/or a Phosphodiesterase-5 Inhibitor","status":"WITHDRAWN","sponsor":"Lung Biotechnology PBC","startDate":"2011-11","conditions":"Pulmonary Arterial Hypertension","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["BPS-MR Tablets, 60mcg","Beraprost Sodium Modified Release Tablet, 60mcg","BPS-MR Tablets, 60 mcg","Beraprost Sodium Modified Release Tablet, 60 mcg"],"phase":"phase_2","status":"active","brandName":"Beraprost Sodium Modified Release","genericName":"Beraprost Sodium Modified Release","companyName":"Lung Biotechnology PBC","companyId":"lung-biotechnology-pbc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Beraprost sodium is a prostacyclin analog that acts on the IP receptor to dilate blood vessels and inhibit platelet aggregation. Used for Pulmonary arterial hypertension, Chronic thromboembolic pulmonary hypertension.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":3,"withResults":3},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}